SAN DIEGO—Investigators from around the country presented their findings at the 120th Annual Meeting of the Triological Society, held in conjunction with the 2017 Combined Otolaryngology Spring Meetings, held here April 28–29, 2017. Here are some research highlights from the event.
Explore this issue:June 2017
Thyroid Cancer Clinical Trials in the United States
In a retrospective analysis of U.S. clinical trials on thyroid cancer performed from 1998 through 2015, researchers found that, of the 73 trials found, 97% were drug studies. Furthermore, they found that 20% of those drug trials were focused on the kinase inhibitors sorafenib and vandetanib, with all other drugs represented in just three or fewer trials, said presenter Anand Devaiah, MD, associate professor of otolaryngology-head and neck surgery at Boston University.
The researchers also found that, among treatment type, 14% of the trials included radiation therapy and 4% involved surgery.